Advertisement

Topics

Latest "Immunomic Therapeutics, Inc.(ITI)" News Stories

16:46 EST 17th February 2019 | BioPortfolio

Here are the most relevant search results for "Immunomic Therapeutics, Inc.(ITI)" found in our extensive news archives from over 250 global news sources.

More Information about Immunomic Therapeutics, Inc.(ITI) on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Immunomic Therapeutics, Inc.(ITI) for you to read. Along with our medical data and news we also list Immunomic Therapeutics, Inc.(ITI) Clinical Trials, which are updated daily. BioPortfolio also has a large database of Immunomic Therapeutics, Inc.(ITI) Companies for you to search.

Showing "Immunomic Therapeutics" News Articles 1–25 of 8,200+

Saturday 16th February 2019

Week in Review: CStone's Hong Kong IPO to Raise $304 Million at $1.5 Billion Valuation Next Week

Deals and Financings • CStone Pharma of Suzhou will raise $304 million next week in its Hong Kong IPO at a valuation of $1.5 billion to advance fourteen clinical-stage oncology candidates;• Shanghai HaiHe Biopharma, an oncology company with ten molecules in clinical trials, announced a $146.6 million funding;• Burning Rock Biotech, a Guangzhou diagnostics company, closed a $126 mill...


Friday 15th February 2019

Company Profile for Novus Therapeutics, Inc.

Novus Therapeutics, Inc. (“Novus”) is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (“ENT”). Novus has two technologies, each that has the potential to be developed for multiple ENT indications. Novus’ lead product candidate (OP0201) is a surfactant-based, drug-device co...

Antibe Therapeutics Reports Q3 2019 Interim Financial and Operating Results

Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Friday, February 15th for the fiscal quarter ended December 31, 2018. The Company’s unaudited fiscal Q3 2019 condensed interim consolidated financial statements and MD&A are available on SEDAR. About Antib...


$MRKR Announces Change in Corporate Headquarters and Access to New Laboratory Facility https://www.prnewswire.com/news-releases/marker-therapeutics-announces-change-in-corporate-headquarters-and-access-to-new-laboratory-facility-300796813.html …

$MRKR Announces Change in Corporate Headquarters and Access to New Laboratory Facility https://www.prnewswire.com/news-releases/marker-therapeutics-announces-change-in-corporate-headquarters-and-access-to-new-laboratory-facility-300796813.html …

Newly formed Arvelle licenses European rights to SK's anti-epileptic cenobamate

Newly formed Arvelle Therapeutics GMBH licensed exclusive European development and commercialization rights to SK Biopharmace...

Cambrooke Therapeutics and Trovita Health Science Announce Strategic Alliance for ENU® Nutrition

Cambrooke Therapeutics, a member of The Ajinomoto Group, and Trovita Health Science, a specialty medical nutrition company, announce a joint marketing

GEN Webinar, Tuesday, March 12 -- Better by Design: Single-Cell Characterization for Enhanced Cell Therapeutics. Register now at: http://ow.ly/CCt130nGRiC pic.twitter.com/2hXqIm3rTV

GEN Webinar, Tuesday, March 12 -- Better by Design: Single-Cell Characterization for Enhanced Cell Therapeutics. Register now at: http://ow.ly/CCt130nGRiC  pic.twitter.com/2hXqIm3rTV

Hoth Therapeutics Announces Pricing of Initial Public Offering and Trading on the Nasdaq

Hoth Therapeutics (NASDAQ:HOTH) has announced the pricing of its initial public offering of 1,250,000 shares of its common stock at an initial offering price to the public of $5.60 per share. As quoted in the press release:  All shares of common stock are being offered by Hoth. In addition, Hoth has granted the underwriters a 30-day option … Continued The post Hoth Therapeutics Announces ...

Five Prime Therapeutics (FPRX) Presents At Guggenheim Healthcare Talks Idea Forum - Slideshow

Medullary Thyroid Cancer – Pipeline Insight, 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Medullary Thyroid Cancer – Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering. Medullary Thyroid Cancer – Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Medullary Thyroid … Continue reading &#...

Impetigo – Pipeline Insight, 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Impetigo – Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering. The report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Impetigo development. The report provides detailed coverage of the … Continue reading →

Degenerative Disc Disease – Pipeline Insight, 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Degenerative Disc Disease – Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering. Degenerative Disc Disease – Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Degenerative Disc … Continue reading ...

Narcolepsy – Pipeline Insights, 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Narcolepsy – Pipeline Insights, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering. Narcolepsy – Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Narcolepsy development. The report provides detailed … Continue re...

RT #STAT3 #DanaFarber #Moffitt #Cancer We seek partners or equity investors. As a matter of fact, we anticipate IPO in the 2nd quarter. be treated through STAT3 inhibition Let me also mention the coupled diagnostics which could be a greater revenue driv

RT #STAT3 #DanaFarber #Moffitt #Cancer We seek partners or equity investors. As a matter of fact, we anticipate IPO in the 2nd quarter. be treated through STAT3 inhibition Let me also mention the coupled diagnostics which could be a greater revenue driver than the therapeutics

Allergy Therapeutics delivers “stronger than expected” first-half growth as it awaits PQ Birch trial data

Allergy Therapeutics is a long-established specialist in the prevention, diagnosis and treatment of allergies

Nektar, Bristol combo drug shows signs of tumor reduction in bladder cancer patients

Nektar Therapeutics said on Friday some patients with advanced bladder cancer treated with a combination of its experimental treatment and Bristol-Myers Squibb Co's immunotherapy, Opdivo, showed signs of tumor reduction in an early-stage study.

FDA Announces Breakthrough Therapy Designation to CymaBay’s Seladelpar for Treatment of Primary Biliary Cholangitis

NEWARK, Calif., Feb. 15, 2019 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for seladelpar for the treatment of early stage primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adult patients with an inadequate response to UDCA, …

Rainier Therapeutics Presents Data on Vofatamab in Patients with Advanced Urothelial Cell Carcinoma (Bladder Cancer) Previously Treated with Chemotherapy at ASCO GU 2019

– Preliminary data from FIERCE-21 Phase 2 trial highlighted in oral presentation supports advancement to pivotal study – – Single agent activity and long-term treatment duration demonstrated – Rainier Therapeutics, Inc., a privately-held clinical stage drug development company, today announced the presentation of preliminary data from ...

FDA accepts Sarepta’s NDA for precision medicine Golodirsen

US precision medicine company Sarepta Therapeutics has announced the US Food and Drug Administration (FDA) has accepted its new drug...Read More... The post FDA accepts Sarepta’s NDA for precision medicine Golodirsen appeared first on Pharmaceutical Technology.

Sarepta Announces FDA Acceptance of Golodirsen NDA for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53

CAMBRIDGE, Mass., Feb. 14, 2019 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced the Food and Drug Administration, Division of Neurology (the Division), has accepted its New Drug Application (NDA) seeking accelerated approval for golodirsen (SRP-4053) and provided a regulatory action date of August 19, 2019. &#...

Insys Founder To Former CEO: ‘You’re Going To Be The Fall Guy’

Insys Therapeutics, which profited wildly from the sale of a powerful fentanyl spray known as Subsys, was under investigation by federal prosecutors for its marketing practices in 2015. At that time the company's founder John Kapoor told then-CEO Michael Babich that Babich would be the one who was going to shoulder the blame -- according to Babich, who has pleaded guilty to one count of mail fraud...

Anima in talks with 'over ten companies' to use its translation control therapeutics platform.

Anima Biotech CEO Yochi Slonim sat down with Proactive Investors at the BIO CEO & Investor Conference in New York.  Israel based Anima Biotech is pioneering translation control therapeutics, a new class of drugs that specifically control protein translation as a novel strategy against "hard and undruggable" targets.

Rap video is latest evidence in Insys trial

A rap video used to motivate Insys Therapeutics’ salesforce into promoting higher doses of its opioid drug Subsys is the latest piece of evidence in the increasingly-bizarre trial of chairman John Kapoor. Kapoor is accused along with other company...

Anchiano's US IPO nets $28.4mm

Anchiano Therapeutics Inc. (developing gene therapies for cancer) netted $28.4mm through an initial public offering of its Am...

PTA-News: Rapid Dose Therapeutics Inc.: Rapid Dose Therapeutics schließt Beratungsvertrag mit Spinnaker Capital Markets ab

Unternehmensmitteilung für den Kapitalmarkt Burlington (pta015/15.02.2019/11:16) - Ontario - 15. Februar 2019 - Rapid Dose Therapeutics Corp. ("RDT" oder die "Gesellschaft") (CSE: DOSE) freut sich ...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks